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ABSTRACT
The receptor tyrosine kinase AXL promotes migration, invasion, and metastasis.
Here, we evaluated the role of AXL in endometrial cancer. High immunohistochemical
expression of AXL was found in 76% (63/83) of advanced-stage, and 77% (82/107)
of high-grade specimens and correlated with worse survival in uterine serous cancer
patients. In vitro, genetic silencing of AXL inhibited migration and invasion but had no
effect on proliferation of ARK1 endometrial cancer cells. AXL-deficient cells showed
significantly decreased expression of phospho-AKT as well as uPA, MMP-1, MMP-2,
MMP-3, and MMP-9. In a xenograft model of human uterine serous carcinoma with
AXL-deficient ARK1 cells, there was significantly less tumor burden than xenografts
with control ARK1 cells. Together, these findings underscore the therapeutic potentials
of AXL as a candidate target for treatment of metastatic endometrial cancer.

[5]. Although chemotherapy is the treatment of choice for
metastatic or recurrent EC, median survival is only about 12
months for these patients [6-8]. High mortality and limited
treatment options underscore the challenge of metastatic
disease. Developing effective treatments will require a better
understanding of EC metastasis and identification of more
effective therapeutic targets.
The receptor tyrosine kinase AXL has been identified
as a novel therapeutic target given its involvement in tumor
invasion and migration. As a member of the TAM family
of receptor tyrosine kinases, AXL contains an extracellular
domain composed of two immunoglobulin-like domains and
two fibronectin type III domains [9, 10]. The extracellular
domain resembles that of adhesion molecules, and
overexpression of AXL causes an adhesive phenotype [11,
12]. Binding of growth arrest specific gene-6 (GAS-6), the
only known ligand for AXL, induces autophosphorylation
of tyrosine residues 779, 821, and 866 [13-15]. Activation

INTRODUCTION
Endometrial cancer (EC) is the most common
gynecologic malignancy in the United States with 60,050 new
cases and 10,470 disease-related deaths projected for 2016.
The prognosis for early-stage cancer has a five-year survival
rate of 80% to 95% [1, 2]. However, about 29% of patients are
diagnosed with aggressive tumors that have spread to regional
lymph nodes or metastasized to more distant areas [1]. In
patients with distant EC, the five-year survival rate is only
17% [1]. The more aggressive variant of type II EC, uterine
serous cancer, accounts for only 10% of all EC cases but is
responsible for 40% of deaths by this disease [3, 4]. Currently,
the standard treatment for EC consists of surgery followed
by hormonal therapy, chemotherapy, and/or radiation
therapy, depending on patient age and comorbidities, tumor
stage and grade, performance status, and prior treatments
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of AXL stimulates several signal transduction pathways,
including MAPK/ERK kinases, PI3K/AKT, NF-κB, and
STAT and promotes proliferation, anti-apoptosis, survival,
cellular migration, invasion, adhesion, and pro-inflammatory
cytokine production [14, 16-21].
AXL is overexpressed or ectopically expressed in
multiple cancers including breast, prostate, ovarian, and
endometrial cancer [10, 22-29]. In tumor cells, AXL overexpression promotes migration and invasion, whereas
AXL inhibition decreases cell invasion and increases
chemosensitivity [29-31]. In vivo, AXL signaling
promotes metastasis in breast, glioma, lung, and ovarian
cancer [24, 32-36]. These findings demonstrate that AXL
is an important driver of tumor metastasis.
AXL overexpression has been reported in human
uterine cancer [27], but the role of AXL in EC progression
has yet to be elucidated. Using both in vitro and in vivo
approaches, we demonstrate that AXL is critical in EC
invasion, migration, and metastasis. Thus, our study
supports the therapeutic potential of targeting AXL to
inhibit metastatic EC.

endometrial cancer tumors, especially in higher-grade and
advanced stage tumors and metastatic sites.
In a subset of 20 patients for whom we had clinicopathological and survival information, 8 patients with low
AXL expression had longer median survival (96 months)
than the 12 patients with high AXL expression (96 vs. 56
months, P= 0.0285, Figure 1B).

AXL promotes invasion and migration of
endometrial cancer cells
To define the role of AXL in endometrial cancer,
we first screened five EC cell lines for AXL expression.
AXL was abundantly expressed in two cell lines
derived from type II metastatic EC, ARK1 and Hec50a
(Figure 2A). In contrast, AXL was expressed at very low
levels in AN3CA (derived from a grade 3 endometrioid
adenocarcinoma), KLE (derived from a poorly
differentiated adenocarcinoma), and Ishikawa (derived
from a well differentiated type I adenocarcinoma) cells
(Figure 2A).
To examine the role of AXL in proliferation of
EC cells, we used short hairpin RNAs (shRNAs) to
generate AXL-deficient metastatic endometrial cancer
cell lines (ARK 1 and Hec50a) as described previously
[37] and confirmed AXL knockdown by Western analyses
(Figure 2B). We then used an XTT-based assay to measure
proliferation of ARK1 cells containing scrambled shRNA
(shSCRM) or AXL-targeting shRNA (shAXL). Over a
period of 4 days, we found no significant difference in
cellular growth curves (Figure 2D). Consistent with this
finding, we examined ARK1 cells transfected with small
interfering RNA (siAXL or siControl, Figure 2C) and
found no difference in growth curves (Figure 2E). Thus,
we conclude that AXL is not necessary for endometrial
cancer cell proliferation in vitro.
To evaluate the contribution of AXL to tumor cell
invasion, we performed matrigel invasion assays and
found that AXL-deficient ARK 1 and Hec50a cells were
significantly less invasive than controls (Figure 3A).
ARK1 cells transfected with AXL siRNA were similarly
inhibited in their invasive ability (Supplementary
Figure S1A). Likewise, shAXL ARK1 and Hec50a and
siAXL ARK1 cells were less able to migrate in a transwell
assay than the respective control cells (Figure 3B and
Supplementary Figure S1B).
We further examined the effects of therapeutic
inhibition of AXL using a small molecule inhibitor
R428[34]. We first confirmed the effectiveness of R428
in inhibiting p-AXL expression after stimulation with
GAS6 (Supplementary Figure S2A). We then found
that pre-treatment of ARK1 with R428 for four hours
inhibited invasion (Supplementary Figure S2B). Thus,
our data shows that AXL plays an important role in
invasion and migration of uterine serous cancer cells
and that its inhibition would significantly hinder these

RESULTS
AXL is upregulated in endometrial cancer tissues
To confirm and extend previous reports of AXL
overexpression in human EC samples, we performed
immunohistochemical analysis of human endometrial
tissue microarrays that included benign endometrial
glands, endometrioid cancer, serous adenocarcinoma, and
several other mixed cancer types and metastases (Table 1
and Figure 1A). Tissues were scored on a 0–3 scale by
the percentage of AXL-positive cells. Our data show that
whereas 24% (15/63) of normal specimens expressed high
levels of AXL (score 2, or 3), 63% (180/287) of primary
type I and type II endometrial carcinoma samples and 86%
(286/332) of endometrial cancer in all stages (primary
tumors and metastases) expressed AXL (P<0.0001
for both, Table 1). Therefore, AXL was more highly
expressed in malignant endometrium than in normal
endometrium. Additionally, tumor samples collected from
metastatic sites showed significantly higher expression
of AXL than normal samples; whereas 85% (11/13) of
metastatic carcinoma samples expressed AXL and 46%
(6/13) received a score of 3, only 43% (27/63) of normal
samples expressed AXL and only 5% (3/63) received a
score of 3 (P=0.0001, Table 1). Advanced-stage and
high-grade endometrial carcinomas also expressed more
AXL than early-stage and low-grade carcinomas. For
example, 19% of stage I carcinomas received an AXL
score of 3, versus 51% of stage III and 38% of stage IV
carcinomas (P=0.0003, Table 1). Similarly, only 14% of
grade 1 carcinomas were scored as 3 versus 45% of grade
3 carcinomas (P<0.0001, Table 1). These results indicate
that AXL expression was significantly elevated in primary
www.impactjournals.com/oncotarget
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Table 1: AXL expression in human endometrial cancer.
Immunohistochemical analysis of AXL staining in normal endometrial glands, human endometrial tumors and metastases.
Analysis of AXL Staining to Endometrial Tumor Parameters
Score

0

1

2

3

Total

36 (57)

12 (19)

12 (19)

3 (5)

63

46 (18)

51 (19)

67 (26)

96 (37)

260

   Serous

2 (8)

5 (21)

6 (25)

11 (46)

24

  Clear-Cell

2 (67)

1 (33)

0

0

3

Mixed

1 (5)

5 (23)

8 (36)

8 (36)

22

Stromal Sarcoma

1 (25)

3 (75)

0

0

4

Carcinosarcoma

0

2 (25)

2 (25)

4 (50)

8

2 (15)

3(23)

2(15)

6(46)

13

  I

35 (16)

37 (18)

99 (47)

41 (19)

212

  II

5 (14)

7 (19)

12 (32)

13 (35)

37

  III

6 (8)

10 (13)

21 (28)

38 (51)

75

   IV

2 (25)

2 (25)

1 (12)

3 (38)

8

  1

20 (35)

10 (17)

20 (34)

8 (14)

58

  2

12 (12)

16 (16)

39 (38)

34 (34)

101

   3

10 (9)

15 (14)

34 (32)

48 (45)

107

Benign/Atrophic Endometrium
Type I
  Endometrioid
Type II

Metastatic Carcinoma
Stage

a

Grade

Values are presented as n (%). AXL staining score: 0, 0% AXL-expressing cells; 1, 1%–19%; 2, 20%–59%; 3, >60%. a Of
the 334 total specimens, stage was available for 332 of these specimens.
processes. We next sought to determine the molecular
mechanism by which AXL regulates EC cell invasion and
migration. We were particularly interested in the PI3K/
AKT pathway because AXL has been reported to regulate
ovarian cancer metastasis through this pathway [24]. To
determine whether PI3K/AKT signaling is affected by loss
of AXL in endometrial cancer cells, we performed Western
blot analyses evaluating levels of AKT phosphorylated
at Ser473 (P-AKT) on shSCRM and shAXL ARK1
and Hec50a cells. Protein expression on western blot
confirmed that AXL-deficient ARK1 and Hec50a cells
have significantly reduced P-AKT and GAS6 expression
than the shSCRM counterpart (Figure 4A).
To determine whether AXL activation in uterine
cancer is ligand dependent, we starved ARK1 and
Hec50a cells for 48 hours. Then exogenous GAS6 was
added at 600ng/ml concentration for 15mins to stimulate
AXL activation. Western blot analysis showed that
exogenous GAS6 induced phosphorylation of AXL in both
endometrial cancer cell lines (Figure 4B).
www.impactjournals.com/oncotarget

To examine components downstream of PI3K/
AKT pathway, we focused on matrix metalloproteinases
(MMPs) because they have been found to be major
contributors to tumor cell invasion and metastasis [38-40].
Expression of MMP-1 and MMP-2 has been reported to
be associated with EC cell invasion [41, 42]. Additionally,
AXL has been shown to regulate MMP-1, MMP-2 and
MMP-9 expression in ovarian cancer [24]. Likewise,
MMP-3 has been associated with vascular invasion in EC
and AXL has been reported to induce MMP-3 expression
in head and neck cancer cell invasion [43, 44]. We also
examined expression of urokinase-type plasminogen
activator (uPA) since it has also been reported to enhance
EC cell invasion via phosphorylation of AKT [45].
We found that AXL-deficient ARK1 cells expressed
significantly less MMP-1, MMP-2, MMP-9, and uPA than
controls (Figure 4C). Similarly, AXL-deficient Hec50a
cells expressed significantly less MMP-1, MMP-2, MMP3, and uPA than control cells (Figure 4C). To assess
functional measures, gelatin zymogram for MMP-2 and
77293
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MMP-9 was performed on Hec50a and ARK1 shSCRM
and shAXL cells. Hec50a shAXL showed significantly
less active MMP-2 and MMP-9, and ARK1 shAXL had
less active MMP-2 than shSCRM cells (Figure 4D). Taken
together, our results suggest that AXL regulates MMPs
and uPA expression through the PI3K/AKT pathway in
EC cells.

ARK1 cells either shAXL or shSCRM. After 35 days,
we performed in vivo evaluation using bioluminescence
imaging (BLI) to ensure tumor growth and metastases
development in the injected mice. BLI quantification
highlighted the difference in the ability of shSCRM and
shAXL ARK 1 to form metastases. Specifically, ARK1
shSCRM had significantly higher mean BLI intensity
(5.9x108±1.7x108) than those injected with ARK1 shAXL
cells (5.1x107±1.1x107), indicating higher tumor burden
(P=0.0085, Figure 5A). After 60 days, we counted and
weighed the tumors. Mice injected with AXL-deficient
cells developed fewer intraperitoneal metastases and
had lower tumor weight than mice injected with AXLexpressing cells (Figure 5B, 5C and 5D). The average
number of peritoneal metastases was significantly reduced
from 47±8 in shSCRM injected mice to 9 ±2 in shAXL
injected mice (P<0.0001, Figure 5B). Likewise, the
average tumor weight was reduced greatly from 598 ±
63mg in shSCRM injected mice to 281 ± 29mg in shAXL

Genetic inhibition of AXL significantly reduces
endometrial cancer metastasis in mice
Finally, we sought to examine the role of AXL in
EC metastasis in vivo. Since advanced-stage EC presents
with intraperitoneal metastasis, we used a mouse model
in which NOD-SCID mice are intraperitoneally injected
with ARK1 cells. In this model, mice develop ascites
and many small metastatic lesions attached to the
mesentery, omentum, and other peritoneal surfaces [46].
We intraperitoneally injected mice with luciferase labeled

Figure 1: High AXL expression in endometrial tumors correlates with lower survival. A. Representative images of AXL
immunohistochemical staining in benign endometrial glands, high grade endometrioid, and serous carcinomas at 20X magnification.
B. Kaplan-Meier curves showing differences in survival between low AXL and high AXL expressing uterine serous tumors. Tumors
expressing low AXL (5-10%, n=8) have survival median of 96 months while tumors expressing high AXL (60-100%, n=12) have
significantly lowered survival of 56 months (P=0.0285).
www.impactjournals.com/oncotarget
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Figure 2: Genetic inactivation of AXL does not affect proliferation of endometrial cancer cell line. A. Western blot analysis

of AXL (140 kDa) and GAS6 (75kDa) expression in a panel of human endometrial cancer cell lines. Vinculin (125 kDA) is shown as a
loading control. B. Western blot analysis of AXL (140 kDa) expression in ARK1 and Hec50a cells stably transfected with shRNA targeting
AXL (shAXL) or scramble control (shSCRM). Heat shock protein 70 (Hsp70, 70 kDa) is shown as a protein loading control. C. Western
blot analysis of AXL (140 kDa) and GAS6 (75kDa) expression in siControl and siAXL ARK1 cells at 72, 96, 120, and 144 hours post
transfection. β-actin (42 kDa) is shown as a loading control. D. Cellular growth curves for ARK1 shSCRM and shAXL cells (n=3). Data are
represented as mean +/- SEM. E. Cellular growth curves for siControl and siAXL ARK1 cells (n=3). Cells were plated into 96 wells plate
for XTT proliferation assay 48hrs after siRNA transfection. Data are represented as mean +/- SEM.
www.impactjournals.com/oncotarget
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Figure 3: AXL is essential to invasion and migration of endometrial cancer cells. A. Matrigel invasion assay of ARK1

and Hec50a shSCRM and shAXL cells. Images were taken after 48h at 20X magnification showing fewer invading cells for AXL
deficient cells. Graphs show quantification of invasion assays (n=3). Data are represented as mean +/- SEM and asterisks indicate
a significant increase or decrease in expression compared with shSCRM as determined by student’s t test (**, P < 0.01; ***, P <
0.001). B. Migration assay using boyden chambers of shSCRM and shAXL ARK1 and Hec50a cells. Images were taken after 48h at
20X magnification illustrating inhibition of shAXL cell migration. Graphs show quantification of migration assays (n=3). Data are
represented as mean +/- SEM and asterisks indicating statistical significance compared to shSCRM as determined by the student’s
t-test (***, P < 0.001; ****, P <0.0001).

www.impactjournals.com/oncotarget
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Figure 4: AXL regulates PI3K/AKT signaling pathway and MMP expression in endometrial cancer cells. A. Western blot

analysis of phospho-AKT (Ser473, 56-60 kDa), total AKT (60 kDa), AXL (140 kDa), and GAS6 (75 kDa) expression in ARK1 and Hec50a
cells expressing shSCRM or shAXL. β-actin (42 kDa) is shown as a loading control. B. Western blot analysis of AXL (140 kDa), phosphoAXL (Tyr702, 140 kDa) and GAS6 (75 kDa) expression in starved ARK1 and Hec50a cells with or without GAS6 stimulation. β-actin
(42 kDa) is shown as a loading control. C. Real time PCR analysis of MMP-1,-2,-3,-9, uPA, and AXL expression in shAXL and shSCRM
endometrial cancer ARK1 and Hec50a cells. Expression values were normalized to 18S and fold changes were calculated over shSCRM
(n=3). Data are represented as mean +/- SEM and asterisks indicate significant increase or decrease in expression compared to shSCRM as
determined by the student’s t-test (**, P < 0.01; ***, P < 0.001; ****, P <0.0001). D. Gelatin zymography assay for pro- and active-MMP2
and MMP-9 activity in conditioned media collected from serum starved Hec50a cells.
www.impactjournals.com/oncotarget
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Figure 5: Genetic inactivation of AXL significantly inhibits endometrial metastasis in mouse model. A. Bioluminescent

imaging (BLI) of mice injected with luciferase-tagged ARK1 shSCRM and shAXL cells at 35 days following injection. Graph on the right
shows quantification of BLI intensity. Data are represented as mean +/- SEM and asterisks indicating statistical significance as determined
by the student’s t-test (**, P < 0.01). B. Representative images of abdominal cavity taken ~60 days after injection with shSCRM and shAXL
ARK1 cells. Note that mice injected with shSCRM cells visually displayed more tumor metastasis throughout the abdominal cavity than
shAXL mice (circled). Graphs depict the average number of all peritoneal metastases >1mm in size per mouse and the average weight of
total tumor nodules from each treatment group (n=9 per group). Data are represented as mean +/- SEM and asterisks depict significant
change in tumor burden as determined by student’s t test (****, P < 0.0001). C. Images of the mesentery from mice injected with shSCRM
or shAXL ARK1 cells. Note that tumor nodules are circled. Graphs on the right depict average number of tumor nodules and tumor weight
from the mesentery alone. Data are represented as mean +/- SEM and asterisks depict significant change in tumor burden as determined by
student’s t test (**, P < 0.01; ***, P < 0.001). D. Images of the omentum from mice injected with shSCRM or shAXL ARK1 cells. Graphs
on the right depict average number of tumor nodules and tumor weight from the omentum alone. Data are represented as mean +/- SEM and
asterisks depict significant change in tumor burden as determined by student’s t test (***, P < 0.001; ****, P < 0.0001).
www.impactjournals.com/oncotarget
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injected mice (Figure 5B, P< 0.0001). We observed
similar reductions in tumor number and weight when the
tumors were divided according to the site of metastasis,
either in the mesentery or omentum (Figure 5C and 5D).
Overall, these findings demonstrate that knockdown of
AXL expression in ARK 1 cells inhibited endometrial
cancer metastasis. This is the first in vivo experiment to
establish the essential role of AXL in the development of
EC metastasis.
We further evaluated whether tumors seen in
the shAXL model expressed AXL, and we found that
a portion of tumors that grew either had AXL protein
expression or a lack of AXL expression. Therefore
tumor growth was due to either incomplete knockdown
or growth despite knockdown (Supplementary Figure
S3A). At the mRNA level, AXL knockdown tumors were
found to have low expression of AXL (Supplementary
Figure S3B). In addition, shAXL tumors had less p-AKT
protein expression, uPA, MMP-1, MMP-2, MMP-3 and
MMP-9 mRNA expression as seen in vitro. To further
confirm whether AXL regulates metastasis rather than
proliferation, Ki67 expression was evaluated in the
xenograft tumors and shAXL tumors had similar Ki67
expression as shSCRM (Supplementary Figure S4). This is
consistent with our findings that AXL inhibition decreases
tumor growth via inhibition of metastasis rather than by
proliferation.

Furthermore, we demonstrated that genetic
knockdown of AXL significantly inhibited EC invasion
and metastasis both in vitro and in vivo. Pharmacological
inhibition using R428 was also used to inhibit endometrial
cancer cell invasion in vitro, suggesting clinical relevance
of AXL inhibition. As in ovarian cancer, reduction of AXL
expression primarily reduced the establishment of new
metastatic lesions during progression of EC metastasis
rather than reducing proliferation of the established
tumors themselves [24]. Immunohistochemical analysis
of Ki-67 expression in ARK1 shAXL and shSCRM
mouse xenografts confirms that AXL knockdown has no
significant effect on Ki-67. This is consistent with our
proliferation data in which AXL displayed no effect on
the proliferation and growth of ARK1 cells. AXL has been
shown to regulate proliferation and survival in a number
of cancers; however, it appears that AXL signaling and
overall biological effect differs depending on tumor type.
This study provides more support that AXL may inhibit
invasion but not proliferation as seen in ovarian cancer
[24]. Although the majority of anti-cancer agents are
directed at growth inhibition, most cancer patients are
affected by metastasis [49]. Few drugs have been proven
effective at treating cancer metastasis [49]. Our data
suggests AXL to be a promising candidate for inhibiting
EC metastasis.
We have demonstrated ligand-dependent activation
of AXL in EC. Starved ARK1 cells had low levels of
endogenous GAS6 and minimal p-AXL. Upon stimulation
with exogenous GAS6, AXL phosphorylation was
induced. Additionally, GAS6 levels correlated with AXL
expression in EC cell lines as well as a decreased level
in cells with genetic inactivation of AXL. Thus indicating
GAS6 to be an important factor to consider with AXL
inhibition. We also showed that AXL regulation of EC
is likely through the PI3K/AKT pathway. Given the
importance of the PI3K/AKT pathway in gynecologic
carcinogenesis, our findings suggest that AXL might be a
novel target to inhibit upstream of this pathway. Moreover,
we demonstrated that silencing AXL significantly
inhibited the expression of proteins involved in the
regulation of the extracellular matrix such as MMPs and
uPA, unveiling the pathway by which AXL mediates
tumor metastasis. Urokinase-type plasminogen activator
(uPA), an important player in the degradation of the
extracellular matrix, is associated with worse prognosis in
EC [45, 50]. Furthermore, uPA has been reported to boost
EC cell invasion via increased levels of p-AKT, p-ERK1/2
and p-p38 [45]. This is the first time that uPA has been
shown to be regulated by AXL, possibly through the
p-AKT pathway. This finding illuminates a more complete
mechanism by which AXL and its downstream proteins
interact to enhance cancer invasion.
Overall, current molecular-targeted agents against
EC exhibited low impact on survival and response in
clinical trials, suggesting that further studies are needed

DISCUSSION
Metastatic and recurrent EC pose challenges to
current therapies as median patient survival is less than
one year [6-8]. Moreover, current chemotherapies for
advanced EC can result in significant morbidity, leading
to poor tolerability and ultimately discontinuation in some
cases [47]. However, advances in the understanding of
the molecular mechanisms underlying cancer have made
it possible to use targeted agents to disrupt cancer cell
progression and survival. This targeted approach may be
able to reduce systemic side effects and improve quality of
life and overall survival for patients [47, 48].
To date, there are few receptor tyrosine kinases that
have been identified as major factors in EC invasion. More
specifically, the biological role of AXL, a receptor tyrosine
kinase, in EC remains largely uncharacterized despite its
promising advances in numerous cancers. In this study,
we confirmed that AXL was significantly upregulated in
EC tissues and correlated with advanced stage and worse
survival. Our sample size for the survival analysis was
limited to 8 patients for the low expression AXL group and
12 for the high AXL expression group, and other confounding
factors such as age, chemoresistance, and other pathology
risk factors were unavailable for analysis. Future studies are
needed to confirm these findings. Nonetheless, this is the
first data to implicate AXL as a clinically relevant prognostic
factor in EC, in particular, associated with worse prognosis.
www.impactjournals.com/oncotarget
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to address the problems with current agents and identify
more effective molecular targets [47]. Taken together, our
data suggest that AXL may be a novel therapeutic target
to inhibit endometrial cancer metastasis. In fact, AXLspecific inhibitors and multi-kinase inhibitors targeting
AXL are already under development for treatment of
several cancers [10]. For example, SKI606 (Bosutinib),
a multi-kinase inhibitor targeting AXL, has been shown
to reduce AXL-specific invasiveness in hepatocellular
carcinoma cells and is in Phase 1 and 2 clinical trials
for metastatic breast cancer [10, 51]. Additionally, R428
(BGB324), a small molecule inhibitor of AXL, used in our
in vitro experiments, is currently in clinical trials in acute
myeloid leukemia and in non-small cell lung cancer. AXL
inhibition via soluble AXL receptors in vivo has also been
shown to reduce ovarian cancer metastasis in mice with
established disease by 63% [24].
There has yet to be any study to target AXL
in advanced EC. Thus, our findings may serve as a
foundation for more studies on AXL in EC since AXL
expression positively correlates with mesenchymal
markers, increased metastasis, and drug resistance in
various solid tumors [10, 32, 52-57]. Thus, these results
may enable targeting AXL not only for invasion, but also
for drug resistance and other associated issues in EC.
In summary, we demonstrate that genetic inhibition
of AXL via shRNA is sufficient to significantly reduce EC
metastatic progression and highlight clinical implications
of AXL therapy for treatment of advanced or recurrent
EC, against which current treatments can be significantly
improved.

tumor cell expression of membranous AXL was scored
semiquantitatively according to the percentage of cells
positive for AXL expression (0 for 0%, 1 for 1-19%, 2 for
20-59%, and 3 for > 60%). For the Washington University
TMA, AXL expression was recorded as a continuous
variable. Data from this TMA was incorporated into Table
1 according to the same scoring system (0 for 0%, 1 for
1-19%, 2 for 20-59%, and 3 for > 60%). For the survival
curve, IHC scores, 5–10% for low and 60–100% for
high, was found to show the greatest survival difference
between groups. Samples included various histologies
including serous, mixed types, and endometrioid. Survival
intervals were calculated from the date of surgery to death,
or censored at the last date of visit.

Cell lines
Endometrial ARK1 cells were provided by ShiWen Jiang (Mercer University School of Medicine,
Savannah, GA, USA). Hec50a cells were a generous
gift from Kimberly Leslie (University of Iowa Carver
College of Medicine, Iowa City, IA, USA). AN3CA
and KLE were obtained from American Type Culture
Collection (Rockville, MD, USA), and Ishikawa cells
were provided by Stuart Adler (Washington University
School of Medicine, St. Louis, MO, USA). All cell lines
were maintained in DMEM (Sigma, St. Louis, MO)
supplemented with 10% heat inactivated FBS (Sigma,
St. Louis, MO) and 1% penicillin and streptomycin
(Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 incubator.

shRNA constructs and lentivirus transduction

MATERIALS AND METHODS

ARK1 and Hec50a were transduced with
lentivirus carrying either oligos encoding an AXL
shRNA or a scrambled sequence (shSCRM). shAXL
oligos were synthesized as previously described
5’-GATTTGGAGAACACACTGA-3’ [37]. A scrambled
sequence was used as a non-targeting shRNA control
5’-AATTGTACTACACAAAAGTAC-3’. Oligos were
cloned into the pSiren RetroQ (BD Bioscience) vector
and infected ARK1 and Hec50a cells, which were then
selected in puromycin (Sigma). For in vivo luciferase
studies, ARK1 cells were transduced with retrovirus
particles encoding for the expression of firefly luciferase
gene (FLuc).

Human Tissue Microarrays and
Immunohistochemical Analysis
Commercial endometrial human tissue microarrays
(TMAs) were obtained from US Biomax (Rockville,
MD). Additionally, a tissue microarray containing sample
cores from 10 patients with uterine papillary serous
carcinoma who had undergone surgery at the University
of Chicago between 1998 and 2007 was obtained from
Ernst Lengyel (University of Chicago, IL) [58]. Another
tissue microarray with corresponding survival data
was constructed from patients treated at Washington
University, under IRB approval. IHC was performed
according to standard protocols. Briefly, slides were
deparaffinized with xylene, rehydrated according to
standard immunohistochemical methods, and stained with
either anti-AXL primary antibody (R&D Systems, AF154;
1:200) or no primary (negative controls). Slides were
stained using the VECTASTAIN ABC system (Vector
Laboratories, Burlingame, CA) and DAB Substrate Kit for
Peroxidase (Vector Laboratories) and counterstained with
hematoxylin. For the US Biomax and U of Chicago TMAs,
www.impactjournals.com/oncotarget

RNA interference
Human AXL siRNA (ON-TARGETplus SMART
pool #L-003104-00-0005) and siControl (ONTARGETplus Non-targeting pool #D-001810-10-05)
were from Dharmacon (Lafayette, CO). One day prior to
transfection, ARK1 cells were plated in a 60 mm dish at
50% confluence in DMEM medium supplemented with
10% FBS without antibiotics. Cells were transfected with
10 nM siRNAs using DharmaFECT 3 transfection reagent
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(T-2003-02) according to the manufacturer’s instructions.
Two days following transfection, ARK1 cells were plated
into a 96-well plate for proliferation assays and harvested
for western blot analysis of AXL expression at 24, 48, 72,
and 96 hrs. Invasion and migration assays were also plated
48 hours following siRNA transfection.

into a 96 well plate in SF media. Conditioned media was
collected 24 hours later. Equal volumes of conditioned
media were run under non-reducing conditions on 10%
gelatin zymogram gels (BioRad). After electrophoresis,
gels were incubated in zymogram renature buffer
(BioRad) for 30 min at RT and then incubated overnight
in zymogram development buffer (BioRad) at 37°C. Gels
were stained for 30 min with Coomassie Brilliant Blue
R250 and destained in 40% methanol and 10% glacial
acetic acid.

Proliferation assays
Cells were plated at densities of 4,000 cells per well
into four 96-well plates in normal medium. Proliferation
was measured at 24, 48, 72, and 96 hours using an
2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium5-carboxanilide inner salt (XTT)-based assay (Roche
Molecular Biochemicals) as previously described [59]. Each
experiment was done in triplicate and repeated three times.

RT-PCR
The RNeasy mini kit (Qiagen) was used to isolate
RNA, 1 µg of which was used to make cDNA using
the Quantitect Reverse Transcription kit (Qiagen)
according to the manufacturer’s protocol. RT-PCR was
performed on 30 ng of cDNA using Fast SYBR Green
Master Mix and the 7500 Fast Real-time PCR System
(Applied Biosystems). Sequences of primers used were:
18S Fwd: 5-GCCCGAAGCGTTTACTTTGA-3 Rev:
5-TCCATTATTCCTAGCTGCGGTATC-3 [60]; AXL
Fwd: 5-GTGGGCAACCCAGGGAATATC-3 Rev:
5-GTACTGTCCCGTGTCGGAAAG-3 [60]; MMP-1:
Fwd: 5-ACACATCTGACCTACAGGATTGA-3 Rev:
5-GTGTGACATTACTCCAGAGTTGG-3 [24]; MMP2 Fwd: 5-GCCCCAGACAGGTGATCTTG-3 Rev:
5-GCTTGCGAGGGAAGAAGTTGT-3 [24]; MMP3 Fwd: 5-TTCCTGGCATCCCGAAGTGG-3 Rev:
5-ACAGCCTGGAGAATGTGAGTGG-3 [61]; MMP9 FWD 5-GGGACGCAGACATCGTCATC-3 REV:
5-TCGTCATCGTCGAAATGGGC-3 [24]; uPA Fwd:
5-AGGGCAGCACTGTGAAATAGATAAGT-3 Rev:
5-CATGGTACGTTTGCTGAAGGA-3 [62]. Fold change
in mRNA expression was calculated by the delta-delta
CT method. Expression of corresponding genes was
normalized to that of the housekeeping gene 18S. Each
value was measured in triplicate, and the experiment was
repeated at least twice.

Transwell invasion and migration assays
Matrigel invasion assays were performed according
to the manufacturer’s protocol (Corning). Briefly, cells
were serum starved for 24 hours and plated onto matrigel
coated boyden chambers. Invasion assays were stained and
analyzed after 16-48 hours. Migration assays were performed
in a similar fashion, in uncoated Boyden chambers. Invaded
cells were quantified by counting the number of invading
cells per high-powered field. After 48 hours, invading cells
on the bottom side of the membranes were fixed, stained,
and counted in four different fields at 20X magnification.
Migration of siRNA-treated ARK1 cells was counted at 10X
magnification due to the distribution pattern of the migrated
cells. The experiments were performed in triplicate wells and
repeated at least three times.
For R428 invasion, ARK1 shSCRM and shAXL
cells were serum-starved overnight and then treated with
either serum-free media or 10 μM R428 (Selleckchem) for
4 hours before plating into Matrigel chambers. Invading
cells were fixed and stained after 48 hours.

Western blot analysis

Orthotopic Model of Uterine Cancer

Protein lysates were prepared from cultured
cells or frozen tumors using a 9M Urea, 0.075 M Tris
buffer (pH 7.6) and quantified using the Bradford assay.
50-100μg of protein was subjected to reducing SDS/PAGE
by standard methods. Western blots were incubated with
primary antibodies against AXL (R&D Systems), P-AXL
(Cell Signaling), GAS-6 (R&D), AKT (Cell Signaling),
and phospho-AKT (Cell Signaling) as needed. To confirm
equal protein loading, blots were probed with antibodies
specific for β-actin (Sigma Aldrich), HSP70 (Thermo
Fisher), or Vinculin (BD Pharmingen).

All procedures involving animals and their care
were performed in accordance with the guidelines of the
American Association for Accreditation for Laboratory
Animal Care and the U.S. Public Health Service Policy
on Humane Care and Use of Laboratory Animals. All
animal studies were also approved and supervised by the
Washington University Institutional Animal Care and Use
Committee in accordance with the Animal Welfare Act,
the Guide for the Care and Use of Laboratory Animals,
and NIH guidelines.
ARK1 cells were transduced with retrovirus
particles encoding firefly luciferase, then transfected with
shSCRM and shAXL as described above. shSCRM and
shAXL ARK1 cells (10x106 cells in 0.5 ml of PBS) were
injected intraperitoneally (i.p.) into female 6-to-8-week

Zymogram
Hec50a shSCRM/AXL cells were starved in serum
free media for 48 hours and 25,000 cells were plated
www.impactjournals.com/oncotarget
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